MedTrace Logo

A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)

NCT05468307 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2025-12-11

No results posted yet for this study

Summary

This study is to investigate the safety and efficacy on TIL engineered with membrane-binding cytokine (GC203 TIL) for the treatment of patients with advanced gynecologic tumors. Autologous TILs from tumor resections or biopsies are first gene modified (engineered with membrane-binding cytokine) and than expanded before i.v. infusion into the patient after NMA lymphodepletion treatment with cyclophosphamide.

Conditions

  • Advanced Gynecologic Tumors
  • TIL Engineered With Membrane-Binding Cytokine
  • Treatment Side Effects
  • Effects of Immunotherapy

Interventions

BIOLOGICAL

Membrane Bound Cytokine Modified TIL

Adoptive transfer of 2x10\^8-1x10\^10 autologous TIL engineered with membrane-binding cytokine to patients i.v. in 30-120 minutes.

Sponsors & Collaborators

  • Shanghai 10th People's Hospital

    collaborator OTHER

  • Shanghai Juncell Therapeutics

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-10
Primary Completion
2024-12-30
Completion
2024-12-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05468307 on ClinicalTrials.gov